US EditionMFDS Clears DeepQure's HyperQure™ for Clinical Trial in Atrial Fibrillation
- DeepQure has received approval from South Korea's Ministry of Food and Drug Safety for a clinical trial of HyperQure, a system designed for treating atrial fibrillation.
- The trial aims to assess the safety and effectiveness of laparoscopic renal denervation in patients with recurrent atrial fibrillation and resistant hypertension.
- HyperQure, developed by Professor Chang-Wook Jeong, uses an extravascular approach to address limitations in traditional techniques.
- This approval expands HyperQure's potential to atrial fibrillation, highlighting its innovative capabilities.
59 Articles
59 Articles
Bennington Banner
MFDS Clears DeepQure's HyperQure™ for Clinical Trial in Atrial Fibrillation
SEOUL, South Korea, July 17, 2025 /PRNewswire/ -- DeepQure announced today that South Korea's Ministry of Food and Drug Safety (MFDS) has approved a clinical trial of HyperQure™ RDM System, the company's novel laparoscopic renal denervation (RDN) system, for the…
MFDS Clears DeepQure's HyperQure™ for Clinical Trial in Atrial Fibrillation - PressReach
SEOUL, South Korea, July 17, 2025 /PRNewswire/ — DeepQure announced today that South Korea’s Ministry of Food and Drug Safety (MFDS) has approved a clinical trial of HyperQure RDM System, the company’s novel laparoscopic renal denervation (RDN) system, for the treatment of atrial fibrillation (AF). The trial is designed to evaluate the safety and efficacy of laparoscopic RDN in patients with recurrent AF following pulmonary vein isolation (PVI) …
Coverage Details
Bias Distribution
- 54% of the sources are Center
To view factuality data please Upgrade to Premium
